anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: computer systems; medicine. SUBSTANCE: method involves producing data set describing individual patient health state including patient identification data, assigning the first and the second access code to the data set. The data sets are processed for making input into a database accessible is carried out through medical institution database management server using the first code. Terminal connection is set for querying personal data with means for accessing the database management server. The third database management server access code is transmitted and the received third code is matched to one of the first two codes. Code equality being proved, data are read from the data set to which the first code, matching the third code, is assigned. The data retrieved from the medical institution patient data set are sent through the database management server to client workstation terminal calling for the data. EFFECT: enhanced effectiveness of service. 12 cl, 1 dwg
Initial Randomization: The initial PT treatment session will occur within 7 days of enrollment in the study. Precise dosage (i.e, number of PT sessions) will be at the discretion of the physical therapist directing the participant's care, up to a maximum of 2-3 sessions per week over the 6-week Phase I treatment period.
One placebo pill x3 daily in a period of 14 days. After 14 days x1 placebo pill daily.
PURPOSE: To obtain the subject administration form by mixing a medicine with a carrier base comprising a water-soluble nonionic cellulose ether and an alkali metal carboxylate, and subsequently press-molding the compound. CONSTITUTION: This solid unit administration form comprises a medicine and <30wt.% of a carrier base material, and has a controlled sustained release pattern on administration. The administration base material comprises (A) one or more of water-soluble nonionic cellulose ethers (e.g. hydroxypropylmethylcellulose having a number-average mol.wt. of at least 50000) and (B) an alkali metal carboxylate (e.g. sodium stearate) in a weight ratio of 1:0.05 to 1:3. The hydroxypropylmethylcellulose occupies 3-25% of the whole weight of the administration form, and has a methoxyl group content of 19-24wt.% and a hydroxypropoxyl group content of 4-12wt.%.
BACKGROUND: Aging-associated left ventricular dysfunction promotes cardiopulmonary fibrogenic remodeling, Group 2 pulmonary hypertension (PH), and right ventricular failure. At the time of diagnosis, cardiac function has declined, and cardiopulmonary fibrosis has often developed. Here, we sought to develop a molecular positron emission tomography (PET)-magnetic resonance imaging (MRI) protocol to detect both cardiopulmonary fibrosis and fibrotic disease activity in a left ventricular dysfunction model.
METHODS AND RESULTS: Left ventricular dysfunction was induced by transverse aortic constriction (TAC) in 6-month-old senescence-accelerated prone mice, a subset of mice that received sham surgery. Three weeks after surgery, mice underwent simultaneous PET-MRI at 4.7 T. Collagen-targeted PET and fibrogenesis magnetic resonance (MR) probes were intravenously administered. PET signal was computed as myocardium- or lung-to-muscle ratio. Percent signal intensity increase and Δ lung-to-muscle ratio were computed from the pre-/postinjection magnetic resonance images. Elevated allysine in the heart (P=0.02) and lungs (P=0.17) of TAC mice corresponded to an increase in myocardial magnetic resonance imaging percent signal intensity increase (P<0.0001) and Δlung-to-muscle ratio (P<0.0001). Hydroxyproline in the heart (P<0.0001) and lungs (P<0.01) were elevated in TAC mice, which corresponded to an increase in heart (myocardium-to-muscle ratio, P=0.02) and lung (lung-to-muscle ratio, P<0.001) PET measurements. Pressure-volume loop and echocardiography demonstrated adverse left ventricular remodeling, function, and increased right ventricular systolic pressure in TAC mice.
CONCLUSIONS: Administration of collagen-targeted PET and allysine-targeted MR probes led to elevated PET-magnetic resonance imaging signals in the myocardium and lungs of TAC mice. The study demonstrates the potential to detect fibrosis and fibrogenesis in cardiopulmonary disease through a dual molecular PET-magnetic resonance imaging protocol.
The invention provides a traditional Chinese medicine combination for treating bone injury and fracture. The traditional Chinese medicine combination for oral administration comprises the following crude drugs: Indian bread, red sage root, cornus officinalis, acanthopanax bark, rhizome of Sichuan lovage, large leaf gentian root, loranthus muberry mistletoe, achyranthes root, safflower, ground beetle, caulis spatholobi, rhizome of drynaria, giant knotweed, psoralea fruit, elderberry, buck grass, cassia twig, earthworm, red peony root, heroubill geranium, ledebouriella root and epimedium; the traditional Chinese medicine combination for external use comprises the following raw materials: anisetree bark, myrrh, frankincense, dipsacus root, notoginseng, safflower, dragon's blood, nux vomica, black catechu, radix aconiti preparata, cassia, caulis impatientis, dahurian angelica root, triperygium wilfordii, Chinese clematis, notopterygium root, earthworm and dried body of scorpion. The traditional Chinese medicine combination has the efficacies of promoting blood circulation to remove blood stasis, promoting reunion of fractured bones, removing stasis to relieve pain and promoting focus repair, and is applicable to the treatment of various types of bone injury and fracture, and is high in cure rate. The traditional Chinese medicine combination ensures that patients are free from the pain of bone fracture and are not required to take strong paregoric. The traditional Chinese medicine combination ensures that callus is rapidly formed and the physiological healing stage is obviously advanced, thereby achieving the purpose of treating bone injury and fracture. The traditional Chinese medicine combination for oral administration has the effects of relieving distension, relieving pain, eliminating stasis, engendering the new and promoting the callus growth, and the traditional Chinese medicine combination for external use can ensure that the callus is rapidly formed and the physiological healing stage is obviously advanced.
Autism is a developmental disorder that can cause severe and pervasive impairment in thinking, feeling, language, and the ability to relate to others. It is usually first diagnosed in early childhood. Children with autism demonstrate repetitive behaviors or interests and deficits in social interaction, verbal communication, and nonverbal communication. In addition, they often have unusual responses to sensory experiences, such as certain sounds or the way objects look. Some symptoms of attention deficit hyperactivity disorder (ADHD), such as inattention, hyperactivity, and impulsivity, are also associated with autism. Atomoxetine is a selective norepinephrine reuptake inhibitor that is used to treat ADHD. It works differently, however, than stimulant drugs and may help to reduce ADHD symptoms in children with autism. This study will evaluate the effectiveness of atomoxetine in treating children with ADHD symptoms associated with autism.

Potential participants will first attend a screening visit, which will include a psychiatric diagnostic interview, a practice session for swallowing pill capsules, a physical exam, an electrocardiogram (ECG), a blood test, and an assessment of pubertal stage. Females of childbearing age will also undergo a urine pregnancy test. In an initial double-blind study phase, eligible participants will be randomly assigned to receive either atomoxetine or placebo for 8 weeks. A baseline visit will include several rating scales, observations, and an interview to assess adaptive functioning. These measures and procedures will be used to keep track of symptoms, side effects, and behavior that could change during the study. Children who are assigned to placebo and do not notice an improvement in their ADHD symptoms will be given the opportunity to receive atomoxetine at the end of 8 weeks. Study visits will occur once a week for 4 weeks, and then every other week for the remainder of the 8 weeks. During these visits, many of the baseline questionnaires and interviews will be repeated. At the Week 8 visit, the physical exam, ECG, blood tests, and some baseline questionnaires will also be repeated. All children who respond well to atomoxetine may continue taking the drug for an additional 10 months. During this time, participants will report to the clinic once a month for the first 4 months, then once at the end of 7 months, and finally once at the end of 10 months. The same measures and procedures that were done during the 8-week phase will be done during the 10-month phase of this study.
PURPOSE: To detect hydrogen peroxide, hydrogen peroxide forming system, peroxidase or peroxidative effect substance by using as color forming agent specific aniline derivative, acid or base and its salt together with oxidizable coupling component in a Trinder reaction. CONSTITUTION: The aniline derivative is represented by a formula. In the formula, R1 is hydrogen lower alkyl, R2 is hydrogen, lower alkyl group, R3 is hydrogen, carboxy, R4 and R4 ' are hydrogen, halogen, R5 is hydrogen, lower alkyl group, R6 is hydroxy, lower alkoxy group. The compound is stable substance, and the substance itself is excellent water soluble or reacted with conventional acid or base to become easy soluble in salt. As the oxidizable coupling component, 4-amonoantipyrine, 2-hydrazo 1-2 are advantageous. Specific aniline derivative, acid or base and its salt and the coupling agent adopt known activator if it is used for detecting H2 O2 , H2 O2 generating system, peroxidase, peroxidative effect substance, and the Trinder reaction is rapid in the degree not requiring for additional activation.
Although cancer and its therapy are well known to be associated with fatigue, the exact nature of cancer-related fatigue remains ill-defined. We previously reported that fatigue-like behavior induced independently by tumor growth and by the chemotherapeutic agent cisplatin is characterized by reduced voluntary wheel running and an intact motivation to expand effort for food rewards. The present set of experiments was initiated to characterize the functional consequences of fatigue induced by chemoradiotherapy in tumor-bearing mice and relate them to changes in the expression of genes coding for inflammation, mitochondria dynamics and metabolism. Two syngeneic murine models of cancer were selected for this purpose, a model of human papilloma virus-related head and neck cancer and a model of lung cancer. In both models, tumor-bearing mice were submitted to chemoradiotherapy to limit tumor progression. Two dimensions of fatigue were assessed, the physical dimension by changes in physical activity in mice trained to run in wheels and the motivational dimension by changes in the performance of mice trained to nose poke to obtain a food reward in a progressive ratio schedule of food reinforcement. Chemoradiotherapy reliably decreased wheel running activity but had no effect on performance in the progressive ratio in both murine models of cancer. These effects were the same for the two murine models of cancer and did not differ according to sex. Livers and brains were collected at the end of the experiments for qRT-PCR analysis of expression of genes coding for inflammation, mitochondria dynamics, and metabolism. The observed changes were mainly apparent in the liver and typical of activation of type I interferon and NF-κB-dependent signaling, with alterations in mitochondrial dynamics and a shift toward glycolysis. Although the importance of these alterations for the pathophysiology of cancer-related fatigue remains to be explored, the present findings indicate that fatigue brought on by cancer therapy in tumor-bearing mice is more physical than motivational.
INTRODUCTION: Sepsis-associated acute kidney injury (SA-AKI) is strongly associated with poor prognosis. We aimed to build a machine learning (ML)-based clinical model to predict 1-year mortality in patients with SA-AKI.
METHODS: Six ML algorithms were included to perform model fitting. Feature selection was based on the feature importance evaluated by the SHapley Additive exPlanations (SHAP) values. Area under the receiver operating characteristic curve (AUROC) was used to evaluate the discriminatory ability of the prediction model. Calibration curve and Brier score were employed to assess the calibrated ability. Our ML-based prediction models were validated both internally and externally.
RESULTS: A total of 12,750 patients with SA-AKI and 55 features were included to build the prediction models. We identified the top 10 predictors including age, ICU stay and GCS score based on the feature importance. Among the six ML algorithms, the CatBoost showed the best prediction performance with an AUROC of 0.813 and Brier score of 0.119. In the external validation set, the predictive value remained favorable (AUROC = 0.784).
CONCLUSION: In this study, we developed and validated a ML-based prediction model based on 10 commonly used clinical features which could accurately and early identify the individuals at high-risk of long-term mortality in patients with SA-AKI.
Root canal procedures will be performed on single-rooted traumatized permanent teeth (both with mature and immature root development) with necrotic pulps and periaoical lesions. Following access opening in each tooth, the root canals will be gently debrided with a crown-down manual technique using K-files according to the radiographically determined working lengths; irrigation with saline was used in all cases. K-files will be only used to remove the necrotic tissue and the softened predentinal layer without excessive removal of mineralized dentin, as this may have further weaken already thin walls of the root canals, particularly those with immature apical development. Subsequently, a reshaping of the canal system, followed by a minor curettage of the periapical area through the canal using barbed broaches will be made in order to partially destruct the periapical lesion and provoke bleeding. Final irrigation will be performed using 2% NaOCl (Chloraxid, Cerkamed, Stalowa Wola-Poland), 0.2% solution of chlorhexidine-digluconate (Curasept 220, Curadent Swiss GmbH, Kriens-Switzerland) and 40% citric acid solution (40% Citric acid, Cerkamed, Stalowa Wola, Poland). The canals will be then dried with sterile paper points and filled with triple-antibiotics paste using a lentula, for a period of seven days. Following this initial disinfection, calcium-hydroxide paste will be placed into the root canals for at least four weeks, for a maximum of six weeks (UltraCal XS, Ultradent Products Inc., South Jordan, UT USA). Apical thirds of the root canals will be obturated either with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA) or MTA+ Cerkamed (Cerkamed, Stalowa Wola, Poland) by forming an apical plug of 3-5 mm of thickness. The correct placement of the apical plug will be assessed radiographically, and the moist cotton pellet was left in the root canal. The next day, the rest of the canal space will be filled with a sealer (Acroseal, Septodont, Saint-Maur des Frosses-France) and gutta-percha points (Guttapercha, VDW GmbH, Munich-Germany) using a lateral compaction technique. Coronal parts of root canal systems will be sealed using glass-ionomer cement (Fuji IX, GC Int., Tokyo, Japan) with a minimum thickness of 1.5-2 mm. The teeth will be restored using composite material (Gradia Direct, GC Int., Tokyo, Japan). Two dentists with many years of clinical experience, and using identical, predetermined treatment protocols will perform all treatments.

The positive clinical outcome will comprise of absence of spontaneous or provoked pain, no discomfort during chewing, no numbness or tenderness to percussion and/or palpation, no altered tooth mobility, tooth crown discoloration or abscess and/or sinus tract. Radiological assessment of the outcomes will be performed according to the analysis of post treatment radiographs (initial, baseline, 3, 6, 12, and 24-months subsequent to obturation) after being photographed using a digital camera Kodak EasyShare Max (Z990) with millimetre measurer in order to obtain interpretation of sizes of periapical lesions during conversion of pixels in mm2 by digital data processing in Adobe Photoshop CS software.
The field of this invention is personalized medicine. A tissue sample is taken from a patient, optionally amplified, and injected into animals, such as mice in a vivarium. Animals receive one or more therapeutic treatments. Animal behaviors are collected, measured and timed using fully automatic, continuous monitoring using per-cage sensors, where behavior recording is free of human, manual actions. Observed behavior is consistent with healthy or unhealthy behaviors specific to the injection site, typically in a specific organ or location in an organ, such as the brain. The injection site may be consistent with the source site from the patient. Both positive and negative baseline behaviors are collected, typically using the same device or method. Treatment selection is responsive to differences between treated and untreated animals, and between treatments, comparing to both the positive and negative baselines, using multi-dimensional analysis, including side effects.
The intervention consists of playing with the smartphone training program using the muscle signals picked up by surface electrodes. The study will run over a period of 5 weeks, with participants playing with the training program at home for 4 weeks.
AIM: This study uses cone beam computed tomography (CBCT) to determine whether pathology in the maxillary sinus (MS) affects the volume of the palatal cavity.
METHODS: 188 individuals, 95 women and 93 men, aged between 17 and 63, were included in the study. MS pathology in the patients and the open-closed status of the maxillary sinus ostium (MSO) were recorded. Palatal volume measurements were performed using open-access ITK-SNAP via CBCT images. Statistical analysis of the study was conducted using SPSS v.21 software (IBM. Chicago. IL. USA), and p<0.05 was considered statistically significant.
RESULTS: The average palatal volume was 1375.29±313.38 mm3 in male patients and 1235.33±250.40 mm3 in females, and it was found to be statistically significant between genders (p=0.001). MS pathology was detected in 114 (60.6%) of the patients. It was determined that the most frequently observed pathology in both the right (n = 58, 30.9%) and left (n = 65, 34.6%) side MS of individuals was mucosal hypertrophy. It was determined that the mean palatal volume was higher when the MSO was closed (p = 0.000). As a result of the correlation analysis, it was shown that the presence of MS pathology had a positive effect in explaining palate volume by 38.6% (R2 = 0.386).
CONCLUSION: Palatal cavity volume was affected by maxillary sinus pathologies. Palatal cavity volume increases in the presence of MS pathologies and when MSOs are closed.
Muscle atrophy due to fragility fractures or frailty worsens not only activity of daily living and healthy life expectancy, but decreases life expectancy. Although several therapeutic agents for muscle atrophy have been investigated, none is yet in clinical use. Here we report that bezafibrate, a drug used to treat hyperlipidemia, can reduce immobilization-induced muscle atrophy in mice. Specifically, we used a drug repositioning approach to screen 144 drugs already utilized clinically for their ability to inhibit serum starvation-induced elevation of Atrogin-1, a factor related to muscle atrophy, in myotubes in vitro. Two candidates were selected, and here we demonstrate that one of them, bezafibrate, significantly reduced muscle atrophy in an in vivo model of muscle atrophy induced by leg immobilization. In gastrocnemius muscle, immobilization reduced muscle weight by an average of ~ 17.2%, and bezafibrate treatment prevented ~ 40.5% of that atrophy. In vitro, bezafibrate significantly inhibited expression of the inflammatory cytokine Tnfa in lipopolysaccharide-stimulated RAW264.7 cells, a murine macrophage line. Finally, we show that expression of Tnfa and IL-1b is induced in gastrocnemius muscle in the leg immobilization model, an activity significantly antagonized by bezafibrate administration in vivo. We conclude that bezafibrate could serve as a therapeutic agent for immobilization-induced muscle atrophy.
Mecidinal specialty in galenic presentation and constituted in particular by a pastille, granule, pill, tablet or the like, adapted to be sucked by the user or with sublingual administration. At least one active product in microdispersed form within the substrate. Method of presenting a therapeutical composition for internal use, particularly for administration per os, in galenic presentation, and containing at least one active principle in solid form adsorbed on a substrate. The active product is distributed therein in the state of finely dispersed microparticles. The method is of the type comprising the phases of: dissolution of the starting active principle in an appropriate solvent; impregnation of the solution thus formed on a food support of appropriate structure pharmaceutically compatible with the active principle; and evaporation of the solvent from the solution adsorbed within the support, provoking reconstitution of the active principle by the formation of microcrystals adsorbed on the walls and within the substrate. The solvent is constituted by a binary system comprising a main solvent, of organic nature, and an adjuvant, of solid type at ambient temperature and soluble in the main solvent. The adjuvant in addition has lubricating properties.
Studies at clinically relevant doses have demonstrated that sertraline blocks the uptake of serotonin into human platelets. In vitro studies in animals also suggest that sertraline is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. In vitro studies have shown that sertraline has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors. The chronic administration of sertraline was found in animals to down regulate brain norepinephrine receptors. Sertraline does not inhibit monoamine oxidase.

Alcohol

In healthy subjects, the acute cognitive and psychomotor effects of alcohol were not potentiated by sertraline.